VEGFA and glioblastoma: Bevacizumab (Avastin®, Genentech/Roche), a recombinant humanized IgG1 monoclonal antibody that prevents the interaction of VEGFA with its receptors and inhibits downstream signaling pathways [9], was the first anti-angiogenic immunotherapy agent approved by the FDA to be used in GBM and in other cancer pathologies [10].